| All Releases |
|---|
 |
United Therapeutics Corporation Reports Third Quarter 2009 Financial Results
Oct 29, 2009
|
20.3 KB
|
| |
SILVER SPRING, Md., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2009.
Revenues for the third quarter of 2009 were $97.2 million, up from $75.0 million for the third quarter of 2008. Net income for the thir...
|
|
|
United Therapeutics Corporation to Announce Third Quarter 2009 Financial Results Before Market Open on Thursday, October 29, 2009
Oct 22, 2009
|
7.9 KB
|
| |
SILVER SPRING, Md., Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2009 third quarter financial results before market open on Thursday, October 29, 2009.
United Therapeutics will host a half-hour teleconference on Thursday, October 29, 2009, at ...
|
|
|
United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
Sep 1, 2009
|
8.6 KB
|
| |
SILVER SPRING, Md., Sept 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that its Board of Directors has approved and declared a stock split. The stock split will be effected in the form of a stock dividend, in which one share of United Therapeutics common stock will be dist...
|
|
|
United Therapeutics Corporation Reports
Second Quarter 2009 Financial Results
Jul 31, 2009
|
222.3 KB
|
| |
Revenues of $84.0 Million, 22.5% Increase over Second Quarter 2008
Net Loss of $2.3 Million, Compared to Net Income of $12.1 Million in Second Quarter 2008
Earnings Before Non-Cash Charges of $32.5 Million, 11.5% Increase over Second Quarter 2008
Silver Spring, MD, July 3...
|
|
|
FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
Jul 30, 2009
|
12.5 KB
|
| |
SILVER SPRING, Md., July 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved TYVASO (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) using the TYVASO Inhalation Sys...
|
|
|
United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
Jul 24, 2009
|
7.5 KB
|
| |
SILVER SPRING, Md., July 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2009 second quarter financial results before market open on Friday, July 31, 2009.
United Therapeutics Corporation will host a half-hour teleconference on Friday, July 31, 2009,...
|
|
|
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
Jun 9, 2009
|
15.3 KB
|
| |
SILVER SPRING, Md. and INDIANAPOLIS, June 9, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and Eli Lilly and Company (NYSE: LLY) today announced the results of a pivotal 16-week study showing that a once-daily dose of tadalafil was generally well tolerated, improved exercise capacity and impro...
|
|
|
FDA Approves ADCIRCA(Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
May 26, 2009
|
12.9 KB
|
| |
SILVER SPRING, Md., May 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved ADCIRCA(TM) (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase ...
|
|
|
United Therapeutics Reports First Quarter 2009 Financial Results
May 1, 2009
|
15.6 KB
|
| |
SILVER SPRING, Md., May 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended March 31, 2009. Total revenues for the first quarter of 2009 were $79.7 million, up from $62.0 million for the first quarter of 2008. Net income for the fir...
|
|
|
Richard Giltner Joins United Therapeutics Board of Directors
Apr 29, 2009
|
8.5 KB
|
| |
SILVER SPRING, Md., April 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the appointment of Mr. Richard Giltner to its Board of Directors as an independent director.
Mr. Giltner has over twenty years of experience in the financial sector. His areas of expertise include int...
|
|
|
U.S. Food and Drug Administration Extends Action Date for Inhaled Treprostinil (Tyvaso) New Drug Application by Three Months
Apr 28, 2009
|
8.4 KB
|
| |
SILVER SPRING, Md., April 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the New Drug Application (NDA) for Tyvaso(TM) (inhaled treprostinil). In a notice received today,...
|
|
|
United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Apr 24, 2009
|
7.7 KB
|
| |
SILVER SPRING, Md., April 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2009 first quarter financial results before market open on Friday, May 1, 2009.
United Therapeutics will host a half-hour teleconference on Friday, May 1, 2009, at 9:00 a.m. Ea...
|
|
|
United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
Mar 16, 2009
|
10.3 KB
|
| |
SILVER SPRING, Md., March 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that, based on its most recent interactions with the U.S. Food and Drug Administration (FDA), the FDA's pending regulatory review of the New Drug Application (NDA) for Tyvaso(TM) (inhaled treprostinil) ...
|
|
|
United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results
Feb 17, 2009
|
130.2 KB
|
| |
Total Annual Revenues of $281.5 Million
Annual Basic and Diluted Net Loss per Share of $1.87
Annual Earnings Before Non-Cash Charges of $5.20 per Basic Share, or $4.77 per Diluted Share
Silver Spring, MD, February 17, 2009: United Therapeutics Corporation (NASDAQ: UTHR) today ...
|
|
|
United Therapeutics to Announce 2008 Fourth Quarter and Annual Financial Results Before Market Open on Tuesday, February 17, 2009
Feb 10, 2009
|
7.7 KB
|
| |
SILVER SPRING, Md., Feb 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2008 fourth quarter and annual financial results before market open on Tuesday, February 17, 2009.
United Therapeutics will host a half-hour teleconference on Tuesday, February 1...
|
|
|
Freedom-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
Nov 17, 2008
|
13.3 KB
|
| |
Conference Call to be Held at 9:00 a.m. Eastern Time on November 17, 2008
Silver Spring, MD, November 17, 2008: United Therapeutics Corporation (NASDAQ: UTHR) announced today the results of the FREEDOM-C trial of oral treprostinil, a sustained-release formulation of treprostinil, in pulmonary arterial hypertension (PAH). Pr...
|
|
|
Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics
Nov 17, 2008
|
72.2 KB
|
| |
INDIANAPOLIS, IN and SILVER SPRING, MD - Eli Lilly and Company (NYSE:LLY) and United Therapeutics Corporation (NASDAQ:UTHR) today announced that the two companies have entered into a license and a supply agreement related to the U.S. commercialization rights for the pulmonary arterial hypertension (PAH) indication of Lilly's molecule, tad...
|
|
|
United Therapeutics Reports Third Quarter 2008 Financial Results
Oct 30, 2008
|
15.5 KB
|
| |
SILVER SPRING, Md., Oct 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2008. Total revenues for the third quarter of 2008 were $75.0 million, up from $59.0 million for the third quarter of 2007. Net income for the...
|
|
|
United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
Oct 23, 2008
|
8.1 KB
|
| |
SILVER SPRING, Md., Oct 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2008 third quarter financial results before market open on Thursday, October 30, 2008.
United Therapeutics will host a half-hour teleconference on Thursday, October 30, 2008, ...
|
|
|
Inhaled Treprostinil New Drug Application Filed by FDA
Sep 3, 2008
|
7.5 KB
|
| |
SILVER SPRING, Md., Sept 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for inhaled treprostinil for the treatment of pulmona...
|
|
|
United Therapeutics' Press Release Archive is furnished solely for historical purposes. Statements made in any release posted here speak only as of the date of such release. We do not undertake any obligation to update any information contained in any release. Our business, financial condition, results of operations and prospects may have changed since the date of any release posted here.
